Profile data is unavailable for this security.
About the company
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
- Revenue in USD (TTM)4.31bn
- Net income in USD-337.00m
- Incorporated2020
- Employees13.30k
- LocationBausch + Lomb Corp520 Applewood CrescentVAUGHAN L4K 4B4CanadaCAN
- Websitehttps://ir.bausch.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LivaNova PLC | 1.19bn | -31.77m | 3.23bn | 2.90k | -- | 2.64 | 191.78 | 2.72 | -0.5911 | -0.5911 | 21.89 | 22.56 | 0.4985 | 2.57 | 6.11 | 408,634.10 | -1.33 | -6.01 | -1.54 | -7.42 | 67.89 | 66.99 | -2.67 | -13.56 | 2.71 | 2.52 | 0.3383 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Tandem Diabetes Care Inc | 770.01m | -141.45m | 3.34bn | 2.40k | -- | 13.74 | -- | 4.34 | -2.17 | -2.17 | 11.82 | 3.76 | 0.8126 | 2.74 | 8.35 | 320,837.10 | -14.93 | -10.08 | -18.48 | -12.23 | 49.28 | 51.77 | -18.37 | -11.59 | 3.01 | -- | 0.5884 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Axonics Inc | 387.14m | -15.95m | 3.43bn | 797.00 | -- | 5.47 | -- | 8.86 | -0.3134 | -0.3134 | 7.76 | 12.29 | 0.5606 | 1.20 | 8.53 | 485,744.00 | -2.31 | -12.67 | -2.52 | -13.76 | 75.25 | 70.04 | -4.12 | -29.68 | 8.04 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
| Procept Biorobotics Corp | 156.33m | -103.37m | 3.44bn | 626.00 | -- | 13.02 | -- | 22.01 | -2.12 | -2.12 | 3.20 | 5.14 | 0.4685 | 1.81 | 4.08 | 249,722.00 | -30.98 | -- | -34.68 | -- | 53.47 | -- | -66.12 | -- | 7.44 | -- | 0.1629 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Integer Holdings Corp | 1.63bn | 98.09m | 4.11bn | 10.50k | 42.58 | 2.69 | 20.65 | 2.52 | 2.88 | 2.88 | 47.86 | 45.52 | 0.5452 | 4.91 | 4.95 | 155,494.60 | 3.28 | 3.28 | 3.53 | 3.53 | 26.54 | 26.94 | 6.01 | 6.40 | 2.01 | 3.74 | 0.4303 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
| Haemonetics Corporation | 1.31bn | 117.56m | 4.49bn | 3.66k | 38.62 | 4.67 | 20.89 | 3.43 | 2.29 | 2.29 | 25.47 | 18.90 | 0.6339 | 2.10 | 6.79 | 357,958.70 | 5.69 | 5.02 | 6.57 | 6.07 | 53.69 | 51.74 | 8.98 | 8.11 | 1.50 | 18.09 | 0.457 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
| TransMedics Group Inc | 296.92m | -10.20m | 4.62bn | 584.00 | -- | 28.90 | 4,219.88 | 15.56 | -0.335 | -0.335 | 8.96 | 4.85 | 0.5874 | 3.08 | 4.93 | 508,422.90 | -2.02 | -16.08 | -2.19 | -17.95 | 62.40 | 65.37 | -3.43 | -40.47 | 8.76 | -- | 0.7607 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| Inspire Medical Systems Inc | 660.91m | -15.73m | 4.72bn | 1.01k | -- | 8.00 | -- | 7.14 | -0.5374 | -0.5374 | 22.46 | 19.85 | 1.05 | 3.14 | 10.01 | 653,721.10 | -2.50 | -11.27 | -2.80 | -12.60 | 84.65 | 84.47 | -2.38 | -13.57 | 7.25 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Merit Medical Systems Inc | 1.28bn | 101.95m | 4.76bn | 6.95k | 46.97 | 3.84 | 24.41 | 3.71 | 1.74 | 1.74 | 21.96 | 21.35 | 0.64 | 2.32 | 7.32 | 184,648.80 | 5.08 | 2.45 | 5.65 | 2.77 | 46.54 | 44.50 | 7.94 | 3.91 | 4.38 | 11.61 | 0.3922 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Bausch + Lomb Corp | 4.31bn | -337.00m | 5.28bn | 13.30k | -- | 0.7926 | 67.69 | 1.22 | -0.9603 | -0.9603 | 12.30 | 18.95 | 0.3527 | 1.91 | 5.28 | 324,360.90 | -2.64 | -- | -3.01 | -- | 60.73 | 61.63 | -7.49 | 1.30 | 1.03 | 0.6549 | 0.4052 | 0.00 | 10.03 | 2.50 | -4,433.33 | -- | 12.38 | -- |
| Lantheus Holdings Inc | 1.37bn | 460.53m | 5.42bn | 834.00 | 11.94 | 5.73 | 10.40 | 3.97 | 6.55 | 6.55 | 19.42 | 13.64 | 0.8587 | 8.78 | 4.71 | 1,637,434.00 | 28.96 | 6.69 | 34.54 | 7.73 | 64.02 | 53.90 | 33.72 | 9.02 | 4.55 | -- | 0.3733 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Glaukos Corp | 326.43m | -140.87m | 5.48bn | 907.00 | -- | 12.04 | -- | 16.80 | -2.88 | -2.88 | 6.68 | 9.04 | 0.3426 | 1.72 | 7.74 | 359,905.20 | -14.78 | -8.73 | -15.91 | -9.35 | 76.18 | 74.77 | -43.16 | -28.69 | 4.68 | -38.38 | 0.4395 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| DENTSPLY SIRONA Inc | 3.94bn | -95.00m | 5.70bn | 15.00k | -- | 1.75 | 22.54 | 1.45 | -0.4468 | -0.4468 | 18.69 | 15.69 | 0.5326 | 2.94 | 6.02 | 262,666.70 | -1.24 | -1.14 | -1.52 | -1.32 | 52.61 | 53.65 | -2.34 | -2.51 | 0.9692 | 3.29 | 0.3908 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
| Novanta Inc | 893.45m | 69.29m | 5.90bn | 2.90k | 85.59 | 8.66 | 50.41 | 6.61 | 1.92 | 1.92 | 24.77 | 18.99 | 0.6778 | 2.99 | 6.11 | 308,086.90 | 5.26 | 5.46 | 5.92 | 6.34 | 45.07 | 43.24 | 7.76 | 7.71 | 1.77 | 4.42 | 0.4319 | 0.00 | 2.41 | 7.49 | -1.58 | 8.21 | 4.19 | -- |
| Stevanato Group SpA | 1.17bn | 147.67m | 6.03bn | 5.64k | 35.86 | -- | 31.32 | 5.13 | 0.5569 | 0.5569 | 4.43 | -- | -- | -- | -- | 208,502.40 | -- | -- | -- | -- | 30.81 | -- | 12.57 | -- | -- | 32.91 | -- | -- | 10.34 | -- | 1.95 | -- | -- | -- |
| Masimo Corp | 1.98bn | 79.10m | 6.74bn | 3.80k | 86.74 | 4.94 | 38.42 | 3.41 | 1.46 | 1.46 | 36.54 | 25.71 | 0.6507 | 2.01 | 5.24 | 519,973.70 | 2.60 | 8.65 | 3.17 | 10.31 | 48.61 | 57.30 | 4.00 | 12.03 | 1.31 | 3.61 | 0.3909 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
Data as of May 24 2024. Currency figures normalised to Bausch + Lomb Corp's reporting currency: US Dollar USD
8.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Investments Canada ULCas of 31 Mar 2024 | 8.19m | 2.33% |
| GoldenTree Asset Management LPas of 31 Dec 2023 | 4.72m | 1.34% |
| Maple Rock Capital Partners, Inc.as of 31 Mar 2024 | 3.75m | 1.07% |
| Icahn Associates Holding LLCas of 31 Mar 2024 | 3.50m | 1.00% |
| River Road Asset Management LLCas of 31 Mar 2024 | 1.89m | 0.54% |
| Alberta Investment Management Corp.as of 31 Mar 2024 | 1.59m | 0.45% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.41m | 0.40% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Mar 2024 | 1.26m | 0.36% |
| Whitebox Advisors LLCas of 31 Mar 2024 | 1.21m | 0.34% |
| Freshford Capital Management LLCas of 31 Mar 2024 | 1.17m | 0.33% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
